TY - JOUR
T1 - Liquid Biopsy in Organ Damage
T2 - small extracellular vesicle chip-based assessment of polytrauma
AU - Wang, Bingduo
AU - Woehler, Aliona
AU - Greven, Johannes
AU - Salzmann, Rebekka J. S.
AU - Keller, Cindy M.
AU - Tertel, Tobias
AU - Zhao, Qun
AU - Mert, Uemit
AU - Horst, Klemens
AU - Lupu, Ludmila
AU - Huber-Lang, Markus
AU - van Griensven, Martijn
AU - Mollnes, Tom Erik
AU - Schaaf, Sebastian
AU - Schwab, Robert
AU - Strassburg, Christian P.
AU - Schmidt-Wolf, Ingo G. H.
AU - Giebel, Bernd
AU - Hildebrand, Frank
AU - Lukacs-Kornek, Veronika
AU - Willms, Arnulf G.
AU - Kornek, Miroslaw T.
PY - 2023/11/15
Y1 - 2023/11/15
N2 - BackgroundDespite major advances in medicine, blood-borne biomarkers are urgently needed to support decision-making, including polytrauma. Here, we assessed serum-derived extracellular vesicles (EVs) as potential markers of decision-making in polytrauma.ObjectiveOur Liquid Biopsy in Organ Damage (LiBOD) study aimed to differentiate polytrauma with organ injury from polytrauma without organ injury. We analysed of blood-borne small EVs at the individual level using a combination of immunocapture and high-resolution imaging.MethodsTo this end, we isolated, purified, and characterized small EVs according to the latest Minimal Information for Studies of Extracellular Vesicles (MISEV) guidelines from human blood collected within 24 h post-trauma and validated our results using a porcine polytrauma model.ResultsWe found that small EVs derived from monocytes CD14+ and CD14+CD61+ were significantly elevated in polytrauma with organ damage. To be precise, our findings revealed that CD9+CD14+ and CD14+CD61+ small EVs exhibited superior performance compared to CD9+CD61+ small EVs in accurately indicating polytrauma with organ damage, reaching a sensitivity and a specificity of 0.81% and 0.97%, respectively. The results in humans were confirmed in an independent porcine model of polytrauma.ConclusionThese findings suggest that these specific types of small EVs may serve as valuable, non-invasive, and objective biomarkers for assessing and monitoring the severity of polytrauma and associated organ damage.
AB - BackgroundDespite major advances in medicine, blood-borne biomarkers are urgently needed to support decision-making, including polytrauma. Here, we assessed serum-derived extracellular vesicles (EVs) as potential markers of decision-making in polytrauma.ObjectiveOur Liquid Biopsy in Organ Damage (LiBOD) study aimed to differentiate polytrauma with organ injury from polytrauma without organ injury. We analysed of blood-borne small EVs at the individual level using a combination of immunocapture and high-resolution imaging.MethodsTo this end, we isolated, purified, and characterized small EVs according to the latest Minimal Information for Studies of Extracellular Vesicles (MISEV) guidelines from human blood collected within 24 h post-trauma and validated our results using a porcine polytrauma model.ResultsWe found that small EVs derived from monocytes CD14+ and CD14+CD61+ were significantly elevated in polytrauma with organ damage. To be precise, our findings revealed that CD9+CD14+ and CD14+CD61+ small EVs exhibited superior performance compared to CD9+CD61+ small EVs in accurately indicating polytrauma with organ damage, reaching a sensitivity and a specificity of 0.81% and 0.97%, respectively. The results in humans were confirmed in an independent porcine model of polytrauma.ConclusionThese findings suggest that these specific types of small EVs may serve as valuable, non-invasive, and objective biomarkers for assessing and monitoring the severity of polytrauma and associated organ damage.
KW - monocytes
KW - trauma
KW - extracellular vesicles
KW - exosomes
KW - liquid biopsy
KW - biomarker
KW - triage
KW - MICROPARTICLES
KW - TRAUMA
U2 - 10.3389/fimmu.2023.1279496
DO - 10.3389/fimmu.2023.1279496
M3 - Article
SN - 1664-3224
VL - 14
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 1279496
ER -